
ReViral Secures $44M in Series C Round of Financing
The company intends to use the newly raised capital to conduct Phase 2 clinical development for sisunatovir, its wholly-owned fusion protein inhibitor, and to progress its N-protein replication inhibitor program into Phase 1.
By
CIO Applications Europe | Monday, August 31, 2020

The company intends to use the newly raised capital to conduct Phase 2 clinical development for sisunatovir, its wholly-owned fusion protein inhibitor, and to progress its N-protein replication inhibitor program into Phase 1.
FREMONT, CA: ReViral, a Stevenage, UK and Durham, NC-based clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel antiviral therapeutics that target respiratory syncytial virus (RSV), raised a US $44m Series C financing.
The round was led by CR-CP Life Science Fund with active participation from OrbiMed Advisors, Andera Partners, Green Sands Equity, Brace Pharma Capital, New Leaf Venture Partners, Novo Holdings, and Perceptive Advisors. In addition to the funding, Jason Zhou M.D., CEO and Managing Director of CR-CP Life Science Fund, joined the ReViral Board of Directors.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
The company plans to use the capital to conduct Phase 2 clinical development for sisunatovir, its wholly-owned fusion protein inhibitor, and to progress its N-protein replication inhibitor program into Phase 1.
Led by Alex Sapir, CEO, ReViral is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics, with an initial focus on the treatment of respiratory syncytial virus (RSV). The company's lead product candidate, sisunatovir, is an orally administered fusion inhibitor currently being examined in two global Phase 2 clinical studies: one in a pediatric patient population and the other in an adult stem-cell transplant patient population. Besides, the company has an N-protein replication inhibitor program in late preclinical development. Both programs were discovered in-house, and the company has maintained worldwide development and commercialization rights.
"We are delighted by the strong financial support from this leading syndicate of healthcare investors, and we welcome Jason to our Board," stated Alex Sapir, CEO, ReViral. "The proceeds from the financing will be used to support Phase 2 clinical development for sisunatovir, our wholly-owned fusion protein inhibitor, and to progress our N-protein replication inhibitor program into Phase 1."
More in News
Weekly Brief
I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info
Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from CIO Applications Europe
THANK YOU FOR SUBSCRIBING


